US6235287B1 - Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments - Google Patents
Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments Download PDFInfo
- Publication number
- US6235287B1 US6235287B1 US09/355,858 US35585899A US6235287B1 US 6235287 B1 US6235287 B1 US 6235287B1 US 35585899 A US35585899 A US 35585899A US 6235287 B1 US6235287 B1 US 6235287B1
- Authority
- US
- United States
- Prior art keywords
- extract
- compound
- formula
- curcuma amada
- concentrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KWHQWFDPRQPHFH-DHDCSXOGSA-N C=C1CCC2C(C)(C)CCCC2(C)C1C/C=C(/C)CC Chemical compound C=C1CCC2C(C)(C)CCCC2(C)C1C/C=C(/C)CC KWHQWFDPRQPHFH-DHDCSXOGSA-N 0.000 description 5
- CBKTUNSAAUKEOY-OYXUYBEVSA-N C=C1CCC2C(C)(C)CCCC2(C)C1C/C=C(/C=O)CC=O.II Chemical compound C=C1CCC2C(C)(C)CCCC2(C)C1C/C=C(/C=O)CC=O.II CBKTUNSAAUKEOY-OYXUYBEVSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/26—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing hydroxy groups
- C07C47/267—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing hydroxy groups containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/05—Alcohols containing rings other than six-membered aromatic rings
- C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/225—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
Definitions
- the present invention relates to certain diterpenes for use as medicaments and to extracts or concentrates of the plant Curcuma amada containing them. Further, the invention relates to pharmaceutical compositions, possibly in the form of dietary supplements or cosmetics, containing at least one of the diterpenes or an extract or concentrate of Curcuma amada, as well as to the use of the diterpenes or the extracts or concentrates of Curcuma amada for the preparation of medicaments for immunomodulation or the alleviation of pain, and specifically for the suppression of hypersensitivity or inflammatory reactions and the treatment or prevention of diseases associated with hypersensitivity reactions.
- the invention also relates to a method of preparing an extract of Curcuma amada.
- Curcuma amada Roxb. family Zingiberaceae
- Mango Ginger is cultivated and grows wild throughout India.
- the herb is rhizomatous with a leafy tuft, 60-90 cm high with white or pale yellow flowers in spikes in the centre of the tuft of leaves.
- Curcuma amada A number of chemicals have been identified as major components of Curcuma amada. Among these are ocimene, dihydro-ocimene, ⁇ -pinene, ⁇ -curcumene, ⁇ -curcumene, linalool, cuminyl alcohol, keto-alcohol, camphor, turmerone, linalyl acetate, safrole, curcumin, myristic acid, car-3-ene, myrcene, 1,8-cineol, limonene, perillene, etc.
- Hypersensitivity is defined as a state of altered reactivity in which the body reacts with an exaggerated immune response to a substance (antigen). Hypersensitivity may be caused by exogenous or endogenous antigens.
- Hypersensitivity reactions underlie a large number of diseases. Amongst these allergic and autoimmune conditions are of great importance. A classification of hypersensitivity diseases is given by Parveen Kumar and Michael Clark in the textbook Clinical Medicine 1
- Type I hypersensitivity reactions are caused by allergens (specific exogenous antigens), e.g. pollen, house dust, animal dandruff, moulds, etc.
- allergens specific exogenous antigens
- allergens e.g. pollen, house dust, animal dandruff, moulds, etc.
- Allergic diseases in which type I reactions play a significant role include asthma, eczema (atopic dermatitis), urticaria, allergic rhinitis and anaphylaxis.
- Type II hypersensitivity reactions are caused by cell surface or tissue bound antibodies (IgG and IgM) and play a significant role in the pathogenesis of myasthenia gravis, Goodpasture's syndrome and Addisonian pernicious anaemia.
- Type III hypersensitivity reactions are caused by autoantigens or exogenous antigens, such as certain bacteria, fungi and parasites.
- Diseases in which type III hypersensitivity reactions play a significant role include lupus erythematosus, rheumatoid arthritis and glomerulonephritis.
- Type IV hypersensitivity reactions are caused by cell or tissue bound antigens. This type of hypersensitivity plays a significant role in a number of conditions, e.g. graft-versus-host disease, leprosy, contact dermatitis and reactions due to insect bites.
- a number of drug classes are available for the treatment of hypersensitivity reactions. Some of these are systemic and some are applied topically.
- corticosteroids are among the most widely used drugs for the treatment of hypersensitivity diseases. Corticosteroids primarily exert their pharmacological action by non-selectively inhibiting the function and proliferation of different classes of immune cells. Hereby hypersensitivity reactions are suppressed. Unfortunately the corticosteroids are associated with a number of serious side effects e.g. immuno-suppression, osteoporosis and skin atrophy (when applied topically).
- R 1 and R 2 are independently CH 2 OH or CHO, and extracts or concentrates of Curcuma amada containing at least one compound of formula I significantly suppress hypersensitivity reactions.
- the present invention provides a pharmaceutical composition, dietary supplement or cosmetic containing at least one compound of formula I or an extract or concentrate of Curcuma amada and a pharmaceutically acceptable carrier.
- a “dietary supplement” is defined, according to the U.S. Food and Drug Administration in the Dietary Supplement Health and Education Act of 1994 (DSHEA).
- the DSHEA gives the following formal definition of a “dietary supplement”:
- a dietary supplement :
- a product other than tobacco that is intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total daily intake, or a concentrate, metabolite, constituent, extract, or combinations of these things.
- the present invention provides the use of at least one compound of formula I or an extract or concentrate of Curcuma amada for preparing a medicament for immunomodulation, for the suppression of hypersensitivity reactions such as IgE mediated allergic reactions and autoimmune reactions, and for the alleviation of pain.
- At least one compound of formula I or an extract or concentrate of Curcuma amada can be used in a method for the treatment or prevention of a hypersensitivity disease in an individual, which comprises administering such substances or a pharmaceutical composition or dietary supplement containing it to said individual; and the invention comprises the use of at least one compound of formula I or an extract or concentrate of Curcuma amada for preparing a medicament for the treatment or prevention of hypersensitivity diseases.
- At least one compound of formula I or an extract or concentrate of Curcuma amada can be used in a method for the treatment or prevention of an autoimmune disorder in an individual, which comprises administering such substances or a pharmaceutical composition or dietary supplement containing it to said individual; and the invention comprises the use of at least one compound of formula I or an extract or concentrate of Curcuma amada for preparing a medicament for the treatment or prevention of autoimmune disorders.
- At least one compound of formula I or an extract or concentrate of Curcuma amada can be used in a method for the treatment or prevention of an IgE mediated allergic reaction or condition in an individual, which comprises administering such substances or a pharmaceutical composition or dietary supplement containing them to said individual; and the invention comprises the use of at least one compound of formula I or an extract or concentrate of Curcuma amada for preparing a medicament for the treatment or prevention of IgE mediated allergic reactions and conditions.
- At least one compound of formula I or an extract or concentrate of Curcuma amada can be used in a method for the alleviation of pain in an individual, which comprises administering such substances or a pharmaceutical composition or dietary supplement containing them to said individual; and the invention comprises the use of at least one compound of formula I or an extract or concentrate of Curcuma amada for preparing a medicament or dietary supplement for the alleviation of pain.
- the invention provides a method of preparing an extract of Curcuma amada, which comprises extracting said plant or parts thereof, preferably the rhizome, with an extraction agent comprising an organic solvent or water or mixtures thereof and subsequently, if necessary, removing the extraction agent to obtain an extract suitable for utilisation.
- FIG. 1 shows the percent inhibition of allergic activity compared to the control for the groups treated with the test extracts in the assay using p.o. administration.
- FIG. 2 shows the percent inhibition of allergic activity compared to the control for the groups treated with the test extracts in the assay using i.v. administration.
- the anti-allergic activity was determined using the Passive Cutaneous Anaphylaxis assay.
- Labda-8(17),12-diene-15,17-dial is preferred among the compounds according to formula I.
- a method for the treatment or prevention of hypersensitivity diseases characterised by the administration of at least one compound of formula I or an extract or concentrate of Curcuma amada.
- the therapeutic action may be relevant to all known diseases associated with hypersensitivity reactions. Below autoimmune disorders and IgE mediated allergic conditions are described more in detail. Besides these specific therapeutic areas the action of at least one compound of formula I or an extract or concentrate of Curcuma amada is relevant to all known conditions and diseases associated with hypersensitivity reactions and the following examples are not limiting with respect to this: infections (viral, bacterial, fungal, parasitic, etc.), cold and flu, contact dermatitis, insect bites, allergic vasculitis, postoperative reactions, transplantation rejection (graft-versus-host disease), etc.
- a method for the treatment or prevention of autoimmune disorders characterised by the administration of at least one compound of formula I or an extract or concentrate of Curcuma amada.
- the therapeutic action may be relevant to all known autoimmune disorders and the following examples are not limiting with respect to this: Autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hemolytic anemias, Grave's disease, myasthenia gravis, Type 1 diabetes mellitus, inflamatory myopathies, multiple sclerosis, Hashimoto's thyreoiditis, autoimmune adrenalitis, Crohn's disease, ulcerative colitis, glomerulonephritis, progressive systemic sclerosis (scleroderma), Sjögren's disease, lupus erythematosus, primary vasculitis, rheumatoid arthritis, juvenile arthritis, mixed connective tissue disease, psoriasis, pemfigus, pemfigoid, dermatitis herpetiformis, etc.
- the therapeutic action may be relevant to all known IgE mediated allergic reactions and conditions and the following examples are not limiting with respect to this: asthma, eczema (e.g. atopic dermatitis), urticaria, allergic rhinitis, anaphylaxis, etc.
- a method for the treatment or prevention of any condition associated with pain characterised by the administration of at least one compound of formula I or an extract or concentrate of Curcuma amada.
- the applicant puts forward the hypothesis that the therapeutic action is related to immunomodulation, possibly to suppressing effects on hypersensitivity reactions.
- a preferred embodiment of the invention is an extract of Curcuma amada.
- Extracts according to the invention can i.a. be obtained by extraction or distillation (e.g. hydro, steam or vacuum distillation) of fresh or dried Curcuma amada or parts thereof, preferably the rhizome. Extraction may be performed with a number of different organic solvents, preferably water miscible solvents, and mixtures thereof with water. The extraction can also be performed with water immiscible solvents, such as alkanes. The extraction can be performed hot or cold by the employment of any extraction technology e.g. maceration, percolation or supercritical extraction.
- any extraction technology e.g. maceration, percolation or supercritical extraction.
- the preferred extraction solvents are pentane, hexane, heptane, acetone, methyl ethyl ketone, ethyl acetate, lower alkanols having 1 to 4 carbon atoms and mixtures thereof with water.
- the preferred extraction temperature is close to the boiling point of the employed solvent due to extraction efficacy, but lower temperatures are also applicable making necessary a longer period of extraction.
- Supercritical extraction (e.g. performed with CO 2 ) is also a preferred mode of extraction.
- the extraction can be made more selective for certain constituents of Curcuma amada thus enhancing or reducing their content in the finished extract.
- the content of phenolic glycosides can be increased by employing a more hydrophilic solvent while the content of sesquiterpenes in the finished product can be enhanced by employing a more lipophilic solvent.
- a second step of processing such as liquid-liquid extraction, column chromatography or any type of distillation, can be employed to remove or to concentrate and possibly isolate any constituent of the extract.
- any constituent of Curcuma amada can be avoided or concentrated in the finished extract, e.g. ocimene, dihydro-ocimene, ⁇ -pinene, ⁇ -curcumene, ⁇ -curcumene, linalool, cuminyl alcohol, keto-alcohol, camphor, turmerone, linalyl acetate, safrole, curcumin, myristic acid, car-3-ene, myrcene, 1,8-cineol, limonene or perillene.
- the content of any component of Curcuma amada can be standardised in the finished extract for the purpose of manufacturing a pharmaceutical composition.
- compounds of formula I may be extracted from other plants than Curcuma amada, such as the seeds of Alpinia galanga (L.).
- At least one compound of formula I or an extract or concentrate of Curcuma amada can be combined with any other active ingredient or plant extract to potentiate the therapeutic action. Consequently, we propose to combine Curcuma amada or parts thereof or extracts or components thereof with eicosapentaenoic acid from fish oils or ⁇ -linolenic acid for any of the above mentioned therapeutic applications of Curcuma amada or parts thereof or extracts or components thereof.
- At least one compound of formula I or an extract or concentrate of Curcuma amada may be mixed with additives such as surfactants, solvents, thickeners, stabilisers, preservatives, antioxidants, flavour etc. to obtain a desirable product formulation.
- the pharmaceutical compositions, dietary supplements or cosmetics according to the invention may further contain such additives.
- the route of administration or dosage form of the formulation and the following examples are not limiting with respect to this: tablets, capsules, fluids, granulates, gels, ointments, liniments, emulsions (e.g. cremes and lotions), sprays (e.g. aerosol), eye drops, etc.
- the composition may also contain surfactants such as bile salts, polyoxyethylene-sorbitan-fatty acid esters or polyalcohol mixed chain-length fatty acid esters for improving dispersibility of the composition in the digestive fluids leading to improved bioavailability or for obtaining the final dosage form of the composition.
- surfactants such as bile salts, polyoxyethylene-sorbitan-fatty acid esters or polyalcohol mixed chain-length fatty acid esters for improving dispersibility of the composition in the digestive fluids leading to improved bioavailability or for obtaining the final dosage form of the composition.
- a) is dispersed in b) while heated to 37° C. on a water bath; c), d) and e) are added. After mixing, f) is added little by little under vigorous mixing.
- d) is melted at approx. 100° C.; and b) is added under continuous heating and mixing. Then c) is added, and the mixture is cooled to room temperature. Finally a) is added, and the formulation is mixed.
- the formulation is filled on tubes, ointment jars or similar.
- Extract 1, 3, 4 and 5 Four extracts of Curcuma amada according to the invention were prepared as described in examples 1, 3, 4 and 5, hereafter correspondingly called Extract 1, 3, 4 and 5, respectively, were investigated in this study.
- the objective of the study was to evaluate the antiallergic effect of the four extracts of Curcuma amada in a well established assay for anti-allergic activity, the Passive Cutaneous Anaphylaxis (PCA) test.
- PCA Passive Cutaneous Anaphylaxis
- the assay was performed according to Goose and Blair 2 .
- Test substances (Extract 1, 3, and 5 ; 500 mg/kg), and vehicle (control) were given by oral administration(p.o.) to a group of 3 Long Evans derived rats, passively sensitized 16 hours earlier by intradermal injection of reaginic (IgE) antiovalbumin serum (0.05 ml). Within 30 minutes after administration of test substance, the animals were challanged i.v. with a mixture of ovalbumin (1 mg) and Evans Blue dye (5 mg) and sacrificed 30 minutes later. Inhibition of the resulting PCA blue colored wheal indicates possible antiallergic activity.
- IgE reaginic antiovalbumin serum
- test substances i.v. administration of the test substances (Extract 1, 3, 4 and 5) and vehicle (control) was performed.
- the test substances were administered i.v. (20 mg/kg) to a group of 3 Long Evans derived rats passively sensitized 16 hours earlier by intradermal injection of reagenic (IgE) antiovalbumin serum (0.05 ml).
- IgE reagenic antiovalbumin serum
- the animals were challanged i.v. with a mixture of ovalbumin (1 mg) and Evans Blue dye (5 mg) and sacrificed 30 minutes later.
- the percent inhibition (mean) compared to the vehicle (control) of the PCA blue colored wheal for the groups treated with the test extracts in the assay using p.o. administration is shown in FIG. 1 .
- the similar results obtained in the assay using i.v. administration is shown in FIG. 2 .
- the objective of the study was to test an extract according to the invention in a well established model of eczema, arachidonic acid induced inflammation in the mouse.
- the assay was performed according to Chang et al 3 . Ear inflammation was induced by topical application of arachidonic acid (5 mg in 20 ⁇ l acetone). Groups of five BALB/c mice were pre-treated 30 minutes before arachidonic acid application and 15 minutes after (post-treatment) with the extract of Curcuma amada prepared in example 3 (1,5 mg per ear per challenge).
- the degree of swelling was recorded four hours after arachidonic acid application.
- the mean percent inhibition of ear swelling was 32% as compared to the control.
- the extract demonstrated a statistically significant effect as compared to the control (p ⁇ 0,05, Wilcoxon rank sum test).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
a) Extract of Curcuma amada: | 0.05 | g | ||
b) |
2.00 | g | ||
c) Ethylenediamine tetraacetic acid, Fluka: | 0.05 | g | ||
d) Benzalkoniumchloride, Sigma: | 0.01 | g | ||
e) Sodium chloride, Merck: | 0.89 | g | ||
f) Milli-Q water, Millipore: | 97.00 | g | ||
a) Extract of Curcuma amada: | 0.3 | g | ||
b) Cremeol E-45, Århus Oliefabrik A/S: | 19.5 | g | ||
c) Volatile Silicone VS72, Bionord A/S: | 9.0 | g | ||
d) Cremeol HF-52 SPC, Århus Oliefabrik A/S: | 1.2 | g | ||
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK1898 | 1998-01-09 | ||
DK0018/98 | 1998-01-09 | ||
PCT/DK1999/000008 WO1999035116A1 (en) | 1998-01-09 | 1999-01-08 | Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
US6235287B1 true US6235287B1 (en) | 2001-05-22 |
Family
ID=8088826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/355,858 Expired - Lifetime US6235287B1 (en) | 1998-01-09 | 1999-01-08 | Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments |
Country Status (7)
Country | Link |
---|---|
US (1) | US6235287B1 (en) |
EP (1) | EP1045822B1 (en) |
JP (1) | JP2002500209A (en) |
AT (1) | ATE239687T1 (en) |
AU (1) | AU748535B2 (en) |
DE (1) | DE69907626D1 (en) |
WO (1) | WO1999035116A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020032643A1 (en) * | 1999-08-05 | 2002-03-14 | Himmelstein Richard B. | Electronic bartering system |
US20020155880A1 (en) * | 2001-04-18 | 2002-10-24 | Paulina Glavich | Gaming device having different sets of primary and secondary reel symbols |
WO2003053167A1 (en) * | 2001-12-11 | 2003-07-03 | Societe Des Produits Nestle S.A. | Composition for promotion of bone growth and maintenance of bone health |
US20040014721A1 (en) * | 2002-06-10 | 2004-01-22 | Oklahoma Medical Research Foundation | Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
US20040072323A1 (en) * | 2001-01-05 | 2004-04-15 | Matsuda Seiichi P.T. | Diterpene-producing unicellular organism |
US6946283B2 (en) | 2001-01-05 | 2005-09-20 | William Marsh Rice University | Ginkgo biloba levopimaradiene synthase |
US20050239480A1 (en) * | 2004-04-21 | 2005-10-27 | Samsung Electronics Co., Ltd. | Positioning apparatus and method of a mobile terminal using a positioning server independently constructed on a network |
US20060141067A1 (en) * | 2004-12-28 | 2006-06-29 | Council Of Scientific & Industrial Research | Anti-allergic herbal formulation |
US20060242054A1 (en) * | 2000-09-20 | 2006-10-26 | Himmelstoin Richard B | Electronic real estate bartering system |
WO2006129323A1 (en) * | 2005-05-30 | 2006-12-07 | Antony Benny | A composition to enhance the bioavailability of curcumin |
US20100325061A1 (en) * | 1999-08-05 | 2010-12-23 | Bartersecurities, Inc. | Electronic Bartering System with Facilitating Tools |
US7883728B2 (en) | 2005-05-30 | 2011-02-08 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
WO2012090205A2 (en) | 2010-12-28 | 2012-07-05 | Kamedis Ltd. | Plant extracts for the treatment and prevention of infections |
US8859020B2 (en) | 2005-05-30 | 2014-10-14 | Benny Antony | Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone |
US9492402B2 (en) | 2005-05-30 | 2016-11-15 | Benny Antony | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
US10286027B2 (en) | 2005-05-30 | 2019-05-14 | Arjuna Natural Extracts, Ltd. | Sustained release formulations of curcuminoids and method of preparation thereof |
US10543277B2 (en) | 2005-05-30 | 2020-01-28 | Arjuna Natural Private Limited | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
US10568925B2 (en) | 2015-01-30 | 2020-02-25 | Dharma Biomedical, Llc | Extracts of Curcuma amada and uses thereof |
US10967031B2 (en) | 2010-12-28 | 2021-04-06 | Kamedis Ltd. | Synergistic herbal compositions with prebiotic properties for treatment of skin infections, allergies and inflammation |
KR20210156387A (en) * | 2020-06-17 | 2021-12-27 | 마루온 주식회사 | Food composition containing pineapple-derived ceramide as an active ingredient and method for manufacturing the same |
US12053438B2 (en) | 2005-05-30 | 2024-08-06 | Arjuna Natural Private Limited | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9903034D0 (en) * | 1999-02-10 | 1999-03-31 | Phytopharm Ltd | Extraction of volatile oils |
TWI290469B (en) * | 2000-07-12 | 2007-12-01 | Medical & Pharm Ind Tech & Dev | Method for manufacturing product with component capable of efficiently preventing inflammation and platelets agglutination form ginger and medical composition with the efficient component |
DE10048596A1 (en) * | 2000-09-30 | 2002-04-25 | Henkel Kgaa | Diterpenes with a labdane structure, useful as antiinflammatory agents in therapeutic and cosmetic compositions for treatment of arthritis, asthma, psoriasis, skin erythema or irritation |
US7041706B2 (en) * | 2002-04-19 | 2006-05-09 | Wilkins Jr Joe S | Method for treating crohn's disease |
EP1587482A4 (en) * | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | Anti-inflammatory compositions and uses thereof |
FR2869230B1 (en) * | 2004-04-23 | 2006-07-28 | Alessio Patrizia D | COMPOSITION FOR PREVENTING OR TREATING CELL DEGENERATION WITH AT LEAST ONE MOLECULE CAPABLE OF MAINTAINING THE REVERSIBILITY OF ADHESION MOLECULE EXPRESSION AND POLYMERIZATION OF ACTIN FIBERS |
JP4849388B2 (en) * | 2005-03-03 | 2012-01-11 | 国立大学法人名古屋大学 | Physiologically active substance and method for producing the same, tasting method of pungent physiologically active substance, and health / medical composition |
JP5535539B2 (en) * | 2009-07-10 | 2014-07-02 | 株式会社F・E・C | Moisturizer |
JP5926895B2 (en) * | 2011-05-11 | 2016-05-25 | 株式会社 資生堂 | Tie2 activator and lymphatic vessel stabilizer |
WO2015063751A1 (en) * | 2013-06-04 | 2015-05-07 | Pt Dexa Medica | Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems |
CN104997947A (en) * | 2015-07-03 | 2015-10-28 | 四川金堂海纳生物医药技术研究所 | Externally-appliedc used for treating thromboangiitis obliterans, and preparation method thereof |
KR102076937B1 (en) * | 2019-08-19 | 2020-02-13 | 연세대학교 산학협력단 | Composition including ocimene or salt thereof as active ingredients for preventing or treating allergic disease or atopic dermatitis |
WO2021034082A1 (en) * | 2019-08-19 | 2021-02-25 | 연세대학교 산학협력단 | Composition for preventing or treating allergic diseases or atopic dermatitis, comprising ocimene, camphor, or salt thereof as active ingredient |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2924345A1 (en) | 1979-06-15 | 1981-01-08 | Nattermann A & Cie | Choleretic Curcuma dry extract and essential oil prodn. - by extn. of Curcuma longa or c.xanthorrhiza with alcohol, dilution of the conc. extract with water, and re-extn. with aliphatic hydrocarbon |
EP0440885A1 (en) | 1990-02-05 | 1991-08-14 | Pt Darya-Varia Laboratoria | Combinations of compounds isolated from curcuma SPP as anti-inflammatory agents |
JPH0585931A (en) | 1991-09-26 | 1993-04-06 | Japan Tobacco Inc | Leucotrienes biosynthesis inhibitor |
US5401777A (en) | 1991-11-14 | 1995-03-28 | Steigerwald Arzneimittelwerk Gmbh | Use of preparations of curcuma plants |
CA2136164A1 (en) | 1995-03-21 | 1996-09-22 | Habib Choudry | Anti-diarrhea composition |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401177A (en) * | 1993-06-01 | 1995-03-28 | Raychem Corporation | Mass termination connector backshell |
-
1999
- 1999-01-08 AU AU19601/99A patent/AU748535B2/en not_active Ceased
- 1999-01-08 JP JP2000527518A patent/JP2002500209A/en active Pending
- 1999-01-08 US US09/355,858 patent/US6235287B1/en not_active Expired - Lifetime
- 1999-01-08 AT AT99900438T patent/ATE239687T1/en not_active IP Right Cessation
- 1999-01-08 EP EP99900438A patent/EP1045822B1/en not_active Expired - Lifetime
- 1999-01-08 WO PCT/DK1999/000008 patent/WO1999035116A1/en active IP Right Grant
- 1999-01-08 DE DE69907626T patent/DE69907626D1/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2924345A1 (en) | 1979-06-15 | 1981-01-08 | Nattermann A & Cie | Choleretic Curcuma dry extract and essential oil prodn. - by extn. of Curcuma longa or c.xanthorrhiza with alcohol, dilution of the conc. extract with water, and re-extn. with aliphatic hydrocarbon |
EP0440885A1 (en) | 1990-02-05 | 1991-08-14 | Pt Darya-Varia Laboratoria | Combinations of compounds isolated from curcuma SPP as anti-inflammatory agents |
JPH0585931A (en) | 1991-09-26 | 1993-04-06 | Japan Tobacco Inc | Leucotrienes biosynthesis inhibitor |
US5401777A (en) | 1991-11-14 | 1995-03-28 | Steigerwald Arzneimittelwerk Gmbh | Use of preparations of curcuma plants |
CA2136164A1 (en) | 1995-03-21 | 1996-09-22 | Habib Choudry | Anti-diarrhea composition |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
Non-Patent Citations (6)
Title |
---|
Chang et al., European Journal of Pharmacology, 142:197-205, 1987. |
Deodhar et al., Indian J. Med. Res., 71:632-634, 1980. |
Goose et al., Immunology, 16:749-760, 1969. |
Kumar, Clinical Medicine, Third Edition, Chapter 2, pp. 147-152. |
Rao et al. J. Agric. Food Chem., vol. 37, No. 3, pp. 740-743, 1989.* |
Zhou et al. Journal of Natural Products, vol. 60, pp. 1287-1293, 1997. * |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060190416A1 (en) * | 1999-08-05 | 2006-08-24 | Barter Securities | Electronic bartering system |
US20080097930A1 (en) * | 1999-08-05 | 2008-04-24 | Richard Himmelstein | Electronic bartering system |
US20020032643A1 (en) * | 1999-08-05 | 2002-03-14 | Himmelstein Richard B. | Electronic bartering system |
US20100325061A1 (en) * | 1999-08-05 | 2010-12-23 | Bartersecurities, Inc. | Electronic Bartering System with Facilitating Tools |
US20080071667A1 (en) * | 1999-08-05 | 2008-03-20 | Richard Himmelstein | System and method for buying and selling employee stock options |
US20020038278A1 (en) * | 1999-08-05 | 2002-03-28 | Himmelstein Richard B. | Electronic bartering system |
US6993511B2 (en) | 1999-08-05 | 2006-01-31 | Barter Securities | Electronic bartering system |
US20080228627A1 (en) * | 1999-08-05 | 2008-09-18 | Richard Himmelstein | Electronic bartering system |
US20060242054A1 (en) * | 2000-09-20 | 2006-10-26 | Himmelstoin Richard B | Electronic real estate bartering system |
US6946283B2 (en) | 2001-01-05 | 2005-09-20 | William Marsh Rice University | Ginkgo biloba levopimaradiene synthase |
US20040072323A1 (en) * | 2001-01-05 | 2004-04-15 | Matsuda Seiichi P.T. | Diterpene-producing unicellular organism |
US7374920B2 (en) | 2001-01-05 | 2008-05-20 | William Marsh Rice University | Ginkgo biloba levopimaradiene synthase |
US7238514B2 (en) | 2001-01-05 | 2007-07-03 | William Marsh Rice University | Diterpene-producing unicellular organism |
US20080020438A1 (en) * | 2001-01-05 | 2008-01-24 | Matsuda Seiichi P | Diterpene-Producing Unicellular Organism |
US20070009996A1 (en) * | 2001-01-05 | 2007-01-11 | William Marsh Rice University | Ginkgo biloba levopimaradiene synthase |
US20020155880A1 (en) * | 2001-04-18 | 2002-10-24 | Paulina Glavich | Gaming device having different sets of primary and secondary reel symbols |
US20050079232A1 (en) * | 2001-12-11 | 2005-04-14 | Elizabeth Offord-Cavin | Composition for promotion of bone growth and maintenance of bone health |
EP2135517A1 (en) * | 2001-12-11 | 2009-12-23 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health |
AU2010201150B2 (en) * | 2001-12-11 | 2011-07-21 | Societe Des Produits Nestle S.A. | Composition for promotion of bone growth and maintenance of bone health |
EP2263480A1 (en) * | 2001-12-11 | 2010-12-22 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health, comprising Mentha extracts |
EP2272382A1 (en) * | 2001-12-11 | 2011-01-12 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health, comprising soybean or soybean extracts |
WO2003053167A1 (en) * | 2001-12-11 | 2003-07-03 | Societe Des Produits Nestle S.A. | Composition for promotion of bone growth and maintenance of bone health |
EP2286675A1 (en) * | 2001-12-11 | 2011-02-23 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health |
EP1325681A1 (en) * | 2001-12-11 | 2003-07-09 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health |
AU2002366734B2 (en) * | 2001-12-11 | 2008-12-11 | Societe Des Produits Nestle S.A. | Composition for promotion of bone growth and maintenance of bone health |
US20090060883A1 (en) * | 2001-12-11 | 2009-03-05 | Nestec S.A. | Composition for promotion of bone growth and maintenance of bone health |
US20040014721A1 (en) * | 2002-06-10 | 2004-01-22 | Oklahoma Medical Research Foundation | Method for using tethered bis(polyhydroxyphenyls) and O-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
US20050239480A1 (en) * | 2004-04-21 | 2005-10-27 | Samsung Electronics Co., Ltd. | Positioning apparatus and method of a mobile terminal using a positioning server independently constructed on a network |
US20060141067A1 (en) * | 2004-12-28 | 2006-06-29 | Council Of Scientific & Industrial Research | Anti-allergic herbal formulation |
US7344739B2 (en) * | 2004-12-28 | 2008-03-18 | Council Of Scientific And Industrial Research | Anti-allergic herbal formulation |
US7736679B2 (en) | 2005-05-30 | 2010-06-15 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US8993013B2 (en) | 2005-05-30 | 2015-03-31 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US7879373B2 (en) | 2005-05-30 | 2011-02-01 | Arjuna Natural Extracis, Ltd. | Composition to enhance the bioavailability of curcumin |
US7883728B2 (en) | 2005-05-30 | 2011-02-08 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US20070148263A1 (en) * | 2005-05-30 | 2007-06-28 | Benny Antony | Composition to enhance the bioavailability of curcumin |
US20110092603A1 (en) * | 2005-05-30 | 2011-04-21 | Benny Antony | Composition to enhance the bioavailability of curcumin |
US20110098361A1 (en) * | 2005-05-30 | 2011-04-28 | Benny Antony | Composition to enhance the bioavailability of curcumin |
WO2006129323A1 (en) * | 2005-05-30 | 2006-12-07 | Antony Benny | A composition to enhance the bioavailability of curcumin |
US8153172B2 (en) | 2005-05-30 | 2012-04-10 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US8197869B2 (en) | 2005-05-30 | 2012-06-12 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US12053438B2 (en) | 2005-05-30 | 2024-08-06 | Arjuna Natural Private Limited | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
US8329233B2 (en) | 2005-05-30 | 2012-12-11 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US8623431B2 (en) | 2005-05-30 | 2014-01-07 | Arjuna Natural Extracto, Ltd. | Composition to enhance the bioavailability of curcumin |
US8859020B2 (en) | 2005-05-30 | 2014-10-14 | Benny Antony | Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone |
US8895087B2 (en) | 2005-05-30 | 2014-11-25 | Arjuna Natural Extracts, Ltd | Composition to enhance the bioavailability of curcumin |
US20100217045A1 (en) * | 2005-05-30 | 2010-08-26 | Benny Antony | Composition to enhance the bioavailability of curcumin |
US9492402B2 (en) | 2005-05-30 | 2016-11-15 | Benny Antony | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
US9861677B2 (en) | 2005-05-30 | 2018-01-09 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US9878040B2 (en) | 2005-05-30 | 2018-01-30 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
US10159654B2 (en) | 2005-05-30 | 2018-12-25 | Arjuna Natural Extracts, Ltd | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
US10543277B2 (en) | 2005-05-30 | 2020-01-28 | Arjuna Natural Private Limited | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
US10286027B2 (en) | 2005-05-30 | 2019-05-14 | Arjuna Natural Extracts, Ltd. | Sustained release formulations of curcuminoids and method of preparation thereof |
US10485843B2 (en) | 2005-05-30 | 2019-11-26 | Arjuna Natural Private Limited | Composition to enhance the bioavailability of curcumin |
US10512616B2 (en) | 2005-05-30 | 2019-12-24 | Arjuna Natural Private Limited | Composition to enhance the bioavailability of curcumin |
US10226499B2 (en) | 2010-12-28 | 2019-03-12 | Kamedis Ltd. | Plant extracts for the treatment and prevention of infections |
US10967031B2 (en) | 2010-12-28 | 2021-04-06 | Kamedis Ltd. | Synergistic herbal compositions with prebiotic properties for treatment of skin infections, allergies and inflammation |
WO2012090205A2 (en) | 2010-12-28 | 2012-07-05 | Kamedis Ltd. | Plant extracts for the treatment and prevention of infections |
US10568925B2 (en) | 2015-01-30 | 2020-02-25 | Dharma Biomedical, Llc | Extracts of Curcuma amada and uses thereof |
KR20210156387A (en) * | 2020-06-17 | 2021-12-27 | 마루온 주식회사 | Food composition containing pineapple-derived ceramide as an active ingredient and method for manufacturing the same |
Also Published As
Publication number | Publication date |
---|---|
EP1045822A1 (en) | 2000-10-25 |
ATE239687T1 (en) | 2003-05-15 |
WO1999035116A1 (en) | 1999-07-15 |
JP2002500209A (en) | 2002-01-08 |
AU1960199A (en) | 1999-07-26 |
EP1045822B1 (en) | 2003-05-07 |
AU748535B2 (en) | 2002-06-06 |
DE69907626D1 (en) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6235287B1 (en) | Certain diterpenes and extracts or concentrates of curcuma amada containing them for use as medicaments | |
ES2279614T3 (en) | NEW SYNERGIC COMPOSITIONS CONTAINING AROMATIC COMPOUNDS AND THERPENOIDS PRESENT IN ALPINIA GALANGA. | |
US6638525B2 (en) | Pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain | |
US20070003645A1 (en) | Novel composition containing extracts of Butyrospermum parkii and the use of such a composition for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity or pain | |
KR20110082292A (en) | Antipuritis and antiance effects of dendropanax morbifera lev. extract | |
KR101934794B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component | |
TW201116286A (en) | Ceramide production enhancer and moisturizing agent | |
JP4105498B2 (en) | A composition effective for prevention and alleviation of symptoms of atopic disease | |
KR101054020B1 (en) | Composition for preventing and treating allergic diseases containing Camellia seed oil extract of longevity situation mushroom | |
JP3540089B2 (en) | Antibody-producing cell suppression enhancer and composition containing the same | |
Berköz | Nigella sativa L. | |
RU2252771C2 (en) | New synergic compositions based on aromatic compounds and therpenoids containing in alpinia galanga |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IDA DEVELOPMENT A/S, DENMARK Free format text: RE-RECORD TO CORRECT THE RECORDATION DATE OF 10/30/1999 TO 09/30/1999 PREVIOUSLY RECORDED AT REEL 10331 FRAME 0251.;ASSIGNORS:WEIDNER, MORTEN SLOTH;PETERSEN, MORTEN JUST;JACOBSEN, NINA;REEL/FRAME:010450/0238 Effective date: 19990913 |
|
AS | Assignment |
Owner name: IDA DEVELOPMENT A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEIDNER, MORTEN SLOTH;PETERSEN, MORTEN JUST;JACOBSEN, NINA;REEL/FRAME:010336/0251 Effective date: 19990913 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: EUROVITA A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTION DEVELOPMENT A/S;REEL/FRAME:012762/0847 Effective date: 20011128 Owner name: ASTION DEVELOPMENT A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IDA DEVELOPMENT A/S;REEL/FRAME:012762/0852 Effective date: 20011128 |
|
AS | Assignment |
Owner name: ASTION DEVELOPMENT A/S, DENMARK Free format text: CHANGE OF NAME;ASSIGNOR:IDA DEVELOPMENT A/S;REEL/FRAME:013117/0180 Effective date: 20020702 Owner name: EUROVITA A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTION DEVELOPMENT A/S;REEL/FRAME:013117/0177 Effective date: 20020510 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |